Healthcare Industry News: Janssen
News Release - September 14, 2007
Canadian Regulatory Authority has Accepted for Review New Drug Submission for CeftobiproleBASEL, SWITZERLAND--(Healthcare Sales & Marketing Network)--Sep 14, 2007 -- Basilea Pharmaceutica Ltd. (Swiss:BSLN.SW ) announced today that the Therapeutic Products Directorate (TPD) of Health Canada has accepted for review the New Drug Submission of ceftobiprole for the treatment of complicated skin and skin structure infections (cSSSI) including diabetic foot infections. The regulatory dossier was submitted by Basilea's license partner Janssen-Ortho, Inc., a Johnson & Johnson company.
Ceftobiprole is currently under review by regulatory authorities in the U.S. and Europe.
Ceftobiprole is being developed through an exclusive worldwide collaboration between Basilea Pharmaceutica Ltd. and Cilag GmbH International.
Basilea Pharmaceutica Ltd. is an integrated biopharmaceutical company headquartered in Basel, Switzerland, listed on the SWX Swiss Exchange (Swiss:BSLN.SW ). Basilea is currently focused on the research, development and commercialization of new antibacterial, antifungal and dermatology drugs.
This communication is intended for information to the financial community only (investors and/or potential investors and their advisors) and expressly or implicitly contains certain forward-looking statements concerning Basilea Pharmaceutica Ltd. and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd. to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd. is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
This press release can be downloaded from www.basilea.com
Source: Basilea Pharmaceutica
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.